Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Abstract: Achieving precise depth control of autonomous underwater vehicles (AUVs) poses a considerable challenge owing to packet losses and ocean current disturbances. Consequently, there is an ...

Model collapse AI training data risk grows as Meta’s Brand Memory ad tools flood the open web with synthetic content, ...

The Council for the Indian School Certificate Examinations (CISCE) has released the ISC Computer Science (Subject Code - 868) for the Year 2027 evaluation cycle. It is designed specifically to make ...

New VentureBeat survey data: 85% of enterprises run contested AI platforms with no single owner, and only 10% can ...

In the AI value chain, application-layer leaders like Palantir and ServiceNow may win long term as chip/cloud margins ...

As AI transforms education, we must redefine intelligence beyond biological limits and embrace cognitive functions across ...

The terminal feel more effective and relevant to my workflow.

Artificial intelligence is rewriting the world, and simultaneously inventing a whole new language to describe how it’s doing it. Sit in on any product meeting, pitch, or panel these days, and you’ll ...

The Internet Corporation for Assigned Names and Numbers (ICANN) today announced that it is planning to change the trust anchor for the Domain Name System (DNS) ...